XK and influenza: While the discovery and engineering of broadly cross-reactive and neutralizing antibodies against influenza could lead to the development of antibody-based therapeutics, vaccine-based approaches will require the design of stabilized NA immunogens that, when administered prophylactically, elicit robust NAI antibody responses to circulating IAV and IBV strains.